Your session is about to expire
← Back to Search
PDS0101 Vaccine + Pembrolizumab for Oropharyngeal Cancer
Study Summary
This trial is studying PDS0101, a vaccine made from specific peptides, either alone or in combination with pembrolizumab, to see how well it works in treating patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had a stroke, heart issues, blood clots, or taken immune system drugs recently.I have not had any other cancer within the last 2 years.I am currently using or have used immunosuppressive medication.My throat cancer is advanced, caused by HPV, and meets specific disease criteria.I have had a bone marrow or organ transplant.I am fully active or restricted in physically strenuous activity but can do light work.My kidney function is within the required range.I have had chemotherapy, radiotherapy, or immunotherapy for head or neck cancer.I am eligible for surgery or combined chemotherapy and radiation with the aim of curing my condition.I am currently being treated for an autoimmune disease.I have not recently had any live vaccines or cancer treatments.I am 18 years old or older.I do not have any uncontrolled illnesses or infections.
- Group 1: Arm B (PDS0101, pembrolizumab)
- Group 2: Arm A (PDS0101)
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current enrollment capacity for this medical experiment?
"Affirmative. Clinicaltrials.gov's records show that the trial was first made public on March 7th 2022 and has been actively searching for participants since then; it is currently seeking 24 volunteers from 1 medical centre."
Is enrollment still open for this research project?
"According to the information provided by clinicaltrials.gov, this medical trial is presently enrolling patients with its initial posting on March 7th 2022 and a recent update taking place on March 11th 2022."
Share this study with friends
Copy Link
Messenger